Clinically, anti-CD19 CAR-T cell therapy combined with lymphodepletion with fludarabine and cyclophosphamide has successfully improved clinical symptoms in patients with SLE by resetting the immune system and normalizing lupus-related parameters133. The gene discussed is CD19; the disease is systemic lupus erythematosus.